MLT 226 Oct. 15: Module 6 Guide to Antibody Identification and Panel Interpretation

Overview of Blood Bank Laboratory Methods and Panel Interpretation

• Curricular Alignment:
  • Blood bank laboratory methodologies and theoretical concepts bridge two primary modules:
  • Module 5: Coverage of other non-ABO/Rh blood group systems.
  • Module 6: Blood bank laboratory methods, including specialized blood bank techniques, alternative means of antibody identification, absorption, dilutions, titrations, and systematic antibody identification.
• Primary Reference Material:
  • Textbook Reference: Chapter 8, Table 8.3, titled Guidelines for interpretation of a panel (located on page 199 in the current edition; corresponding to page 197 or pages 201/232 in earlier editions).
  • Primary Panel Walkthrough Examples:
  • Panel 8.1 and Panel 8.2 on page 200 (illustrating single antibody identification: anti-$K$).
  • Panel 8.3 on page 203 (illustrating complex multiple antibody identification: anti-$\text{E}$ and anti-$\text{Fy}^\text{a}$).

Step 1: Evaluating the Autocontrol (AC)

• Primary Diagnostic Step: The initial step in evaluating an antibody panel is examining the result of the autocontrol (AC).
• Negative Autocontrol:
  • Indicates the absence of detectable autoantibodies coating the patient's own circulating red blood cells.
  • Directs the investigation toward an alloantibody (or multiple alloantibodies) directed against foreign red cell antigens.
• Positive Autocontrol:
  • Signals one of two distinct clinical conditions:
  1. Autoantibody Presence: An autoantibody targeting self-antigens on the patient's red blood cells.
  2. Delayed Hemolytic Transfusion Reaction (DHTR): If reactivity occurs specifically in the Anti-Human Globulin ($\text{AHG}$) phase following recent transfusion exposure, donor red cells may be sensitized by an alloantibody produced in a secondary immune response.

Step 2: Evaluating the Phase of Reactivity

• Immediate Spin ($\text{IS}$) Phase:
  • Immunoglobulin Class: Predominantly represents IgM antibodies.
  • Clinical Significance: Typically clinically insignificant (non-reactive at core body temperature and generally incapable of causing immune red cell destruction in vivo).
• $37^\circ\text{C}$ Phase (Incubation Phase):
  • Immunoglobulin Class: Typically indicates IgG antibodies, though very potent, high-titer IgM antibodies can occasionally display extended reactivity into this phase.
  • Common Specificities: Frequently associated with antibodies within the Rh blood group system, which are notorious for exhibiting reactivity at $37^\circ\text{C}$.
• Anti-Human Globulin ($\text{AHG}$) Phase:
  • Immunoglobulin Class: Reflects IgG antibodies.
  • Clinical Significance: Clinically significant; capable of causing acute or delayed hemolytic transfusion reactions and hemolytic disease of the fetus and newborn ($\text{HDFN}$).

Step 3: Assessing Reaction Strengths and Dosage Effects

• Uniform Reaction Strength Across Isolated Cells:
  • If reactions exhibit uniform strength ($\text{e.g., all } 2+$) across only a few panel cells, the pattern strongly indicates a single antibody.
  • Typically points toward the Rh system or Kell ($\text{K}$) system (most commonly anti-$K$), as these antibodies often demonstrate consistent reactivity and do not prominently show dosage in standard panels.
• Variable Reaction Strengths Across Cells:
  • Variable strengths ($\text{e.g., varying between } 1+, 2+, \text{ and } 3+$) indicate one of two diagnostic scenarios:
  1. Multiple Antibodies: Presence of more than one antibody specificity reacting with different antigens on the panel cells.
  2. Dosage Effect: A single antibody reacting more strongly with red blood cells expressing double dose (homozygous expression) of an antigen than with cells expressing a single dose (heterozygous expression).
• Dosage Characteristics Across Specific Blood Group Systems:
  • Systems Showing Strong Dosage:
  • Duffy System ($\text{Fy}^\text{a}, \text{Fy}^\text{b}$): Classic dosage effect; homozygous cells react noticeably stronger than heterozygous cells.
  • Kidd System ($\text{Jk}^\text{a}, \text{Jk}^\text{b}$): Notorious for displaying strong dosage.
  • $M$ Antigen ($\text{MNS}$ System): Characterized as fickle. When reacting as an IgM antibody, it is typically clinically insignificant. However, when reacting in the IgG ($\text{AHG}$) phase, it becomes clinically significant and displays prominent dosage.
  • Rh System Dosage Nuances:
  • Little $c$ ($c$): Known to display dosage effects and can be weak or variable in reactivity.
  • Big $C$ ($C$): Can show dosage in some panel contexts.
  • Big $D$ ($D$): Never demonstrates dosage.
  • Big $E$ ($E$): Rarely exhibits dosage.
  • Little $e$ ($e$): Reacts strongly throughout panels due to high antigen prevalence; approximately $98\%$ of the general population possesses the little $e$ antigen. Consequently, anti-$e$ is uncommon and challenging to work with due to the difficulty of finding antigen-negative units.

Step 4: Antigen Exclusion (Rule-Out Criteria and Exceptions)

• Foundational Rules for Rule-Outs:
  • Rule 1: Antigens can only be ruled out on panel cells that yield an entirely negative reaction across all phases. Positive reactions must never be used to rule out an antibody.
  • Rule 2: Rule-outs must be performed using homozygous cells (double dose) to avoid missing weakly reactive antibodies exhibiting dosage.
  • Rule 3: The current laboratory standard mandates two homozygous negative cells ($2$ homozygous exclusions) to definitively rule out an antibody specificity (updating the older historical protocol of ruling out with only $1$ cell).
• Exceptions to Homozygous Rule-Out Requirements:
  • The Kell ($K$) System Exception:
  • The high-incidence antigen little $k$ is present in approximately $99\%$ of the population, meaning only about $1\%$ of individuals are homozygous for big $K$ ($KK$ genotype).
  • Finding homozygous $K$ ($K+k-$) panel cells is exceptionally rare ("like gold"); these cells must be conserved carefully.
  • Due to this statistical rarity, exclusions for anti-$K$ may be performed using heterozygous cells ($K+k+$), or by relying on a single homozygous $K+k-$ cell if only one is available.
  • Anti-$D$ Masking Big $E$ and Big $C$:
  • When a patient produces potent anti-$D$, finding homozygous cells for big $E$ ($E$) or big $C$ ($C$) that are simultaneously $D$-negative can be extraordinarily difficult, representing a major practical panel limitation.

Step 5: Antibody Confirmation (The Rule of Twos)

• Shift from Historical Standards:
  • Historically, blood banks employed the Rule of Threes ($3$ antigen-positive cells reacting positively and $3$ antigen-negative cells reacting negatively, achieving a $p$-value of $p \le 0.05$).
  • Modern protocol utilizes the Rule of Twos:
  • Confirmation requires a minimum of two homozygous antigen-positive cells demonstrating a positive reaction.
  • Confirmation requires a minimum of two antigen-negative cells demonstrating a negative reaction.
  • Insufficient Criteria Protocol: If the panel cells do not fulfill the required rule of twos, the technologist must pull and test additional selective panel cells until the criteria are satisfied.

Step 6: Patient Phenotyping and Transfusion Caveats

• Patient Phenotype Requirement:
  • Once an antibody is provisionally identified, the patient's red blood cells must be antigen-typed (phenotyped).
  • To confirm the identity of an alloantibody, the patient must be antigen-negative for the corresponding target antigen.
• The Three-Month Transfusion Caveat:
  • Patient antigen typing is invalid if the patient has received a red blood cell transfusion within the preceding three months ($3\text{ months}$ / $90\text{ days}$).
  • Mechanism: Transfused donor red blood cells circulate alongside the patient's native red blood cells, creating two distinct red blood cell populations.
  • Observed Serological Reaction: Antigen typing tests in transfused patients frequently yield mixed-field reactivity due to agglutination of donor cells against unagglutinated patient cells (or vice versa).
• Resolution Utilizing Transfused Unit Retention Segments:
  • If the patient was transfused internally at the same facility and retention segments from the transfused units remain available, the blood bank can antigen-type the donor unit segments directly.
  • Demonstrating that the transfused donor units were positive for the antigen in question provides formal justification for the observed mixed-field typing results.

Panel Analysis: Single vs. Multiple Antibodies

• Pattern Matching Application:
  • Matching the panel reactivity pattern directly to an antigen profile sheet is only valid for single antibodies.
  • In cases involving multiple antibodies, pattern matching fails because overlapping reactivities produce irregular, non-matching reaction distributions across the panel.
• Single Antibody Example (Panel 8.1 & 8.2, Page 200 - Anti-$K$):
  • Panel 8.1 depicts raw panel results without exclusions; Panel 8.2 displays the same panel with homozygous exclusions executed.
  • Reactivity exactly mirrors the distribution of $K$-positive cells: every $K$-positive cell produces a positive agglutination reaction, while every $K$-negative cell produces no reaction.
• Multiple Antibody Example (Panel 8.3, Page 203 - Anti-$E$ and Anti-$\text{Fy}^\text{a}$):
  • Demonstrates the cumulative effects of multiple specificities and dosage on individual panel cells:
  • Cell 3 ($3+$ Reaction): The cell is homozygous for big $E$ ($E+$) and negative for $\text{Fy}^\text{a}$ ($\text{Fy(a-)}$). Reactivity is driven solely by anti-$E$.
  • Cells 4, 6, 7, and 9 ($1+$ to $2+$ Reactions): All these cells are positive for $\text{Fy}^\text{a}$, but display variable strengths:
    • $2+$ Reactions: Occur on cells that are homozygous for $\text{Fy}^\text{a}$ ($\text{Fy(a+b-)}$; lack $\text{Fy}^\text{b}$), yielding stronger reactions due to double dosage.
    • $1+$ Reactions: Occur on cells that are heterozygous for $\text{Fy}^\text{a}$ ($\text{Fy(a+b+)}$; express both $\text{Fy}^\text{a}$ and $\text{Fy}^\text{b}$), yielding weaker reactions due to single dosage.
  • Cell 5 ($3+$ Reaction): The cell possesses both big $E$ and homozygous $\text{Fy}^\text{a}$. Simultaneous agglutination caused by anti-$E$ and anti-$\text{Fy}^\text{a}$ results in an intensified $3+$ agglutination grade.

Methodology and Gel Testing Interpretation

• Gel Testing Methodology:
  • Antibody identification panels are frequently performed utilizing gel test cards rather than traditional tube agglutination.
  • Reactions in gel cards are graded using standardized reading cards that delineate agglutination strengths based on the migration of red blood cells through the dextran-acrylamide gel matrix (ranging from negative pellets at the bottom to $4+$ bands at the top).

Questions & Discussion

• Query on Panel Interpretation Reference:
  • Question/Context: Identifying the specific textbook location for panel interpretation guidelines in both older and newer textbook editions.
  • Response: Guidelines are outlined in Table 8.3 under Guidelines for interpretation of a panel, situated on page 199 in the newer edition, and corresponding to page 197 (or pages 201/232) in earlier editions within Chapter 8.
• Query on Clinical Significance of Immediate Spin (IS) Reactivity:
  • Question: Is reactivity observed at immediate spin (IgM antibodies) clinically significant?
  • Response: No, IgM antibodies reacting at immediate spin are not clinically significant.
• Query on Variable Reaction Strengths in Duffy-Positive Cells:
  • Question: Why are some $\text{Fy}^\text{a}$-positive panel cells reacting at a $1+$ strength while others react at a $2+$ strength in Panel 8.3?
  • Response: This variation represents dosage. Cells reacting at $2+$ are homozygous for $\text{Fy}^\text{a}$ ($\text{Fy(a+b-)}$), while cells reacting at $1+$ are heterozygous ($\text{Fy(a+b+)}$).
• Query on Cell 5 Reactivity in Multiple Antibody Panels:
  • Question: What explains the intense $3+$ reaction observed on cell number 5 in Panel 8.3?
  • Response: Cell 5 expresses both the big $E$ antigen and homozygous $\text{Fy}^\text{a}$ antigen, meaning both anti-$E$ and anti-$\text{Fy}^\text{a}$ are reacting simultaneously against that cell.
• Query on Validity of Antigen Typing Transfused Patients:
  • Question: Why is patient antigen typing invalid if red blood cells have been transfused within the previous three months, and what serological pattern is expected?
  • Response: The typing is invalid because circulating donor red blood cells remain present in the patient's vascular system, resulting in typing of both donor and recipient cells simultaneously. This dual population manifests serologically as mixed-field reactivity.